Market research
TTOO T2 Biosystms Inc
PINK USD Healthcare
Latest close
As of 26 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 8.18
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 20K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- 8.18
About
About T2 Biosystms Inc
T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.
Research context
T2 Biosystms Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TTOO discussion.
5 years, 6 months ago
T2 Biosystems, Inc is currently in a long term downtrend where the price is trading 30.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.5.
T2 Biosystems, Inc's total revenue rose by 153.8% to $8M since the same quarter in the previous year.
Its net income has increased by 29.4% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 10.0% to $-9M since the same quarter in the previous year.
Based on the above factors, T2 Biosystems, Inc gets an overall score of 4/5.